Plus Therapeutics Inc PSTV.OQ PSTV.O is expected to show a rise in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2024
The Austin Texas-based company is expected to report a 22.3% increase in revenue to $1.517 million from $1.24 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Plus Therapeutics Inc is for a loss of 56 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Plus Therapeutics Inc is $32.00, above its last closing price of $1.35.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -0.46 | -0.53 | -0.56 | Missed | -5.7 |
Jan. 1 0001 | -1.08 | -1.09 | -0.75 | Beat | 31.2 |
Dec. 31 2023 | -0.83 | -1.07 | -0.84 | Beat | 21.7 |
Sep. 30 2023 | -1.02 | -1.12 | -1.00 | Beat | 10.9 |
Jun. 30 2023 | -1.93 | -1.91 | -0.59 | Beat | 69.2 |
Mar. 31 2023 | -1.91 | -1.90 | -2.10 | Missed | -10.5 |
Dec. 31 2022 | -1.50 | -1.80 | -3.30 | Missed | -83.3 |
Sep. 30 2022 | -3.02 | -3.04 | -2.85 | Beat | 6.2 |
This summary was machine generated November 2 at 03:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。